Mesoblast (NASDAQ: MESO) shares are climbing premarket on Monday after the company released clinical trial results for its drug rexlemestrocel-L, showing promising signs.
Mesoblast’s US-listed shares are up 77.48% at $15.37 after its Australian-listed shares closed 14.29%.
The results from the DREAM-HF randomised controlled Phase 3 trial showed that a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. The trial enrolled 537 treated patients with chronic heart failure and reduced left ventricular ejection fraction.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Since existing therapies have minimal or no benefit on these endpoints, Mesoblast feels the outcomes may signal a breakthrough in addressing the unmet needs in patients with chronic heart failure.
Heart attacks and strokes were reduced by 60% over an average follow-up period of 30 months following a single dose of rexlemestrocel-L in the group of 537 patients with New York Heart Association class II or III chronic heart failure.
Rexlemestrocel-L significantly reduced Major Adverse Cardiovascular Events (MACE) by 30% compared to controls across the population of 537 patients.
Mesoblast said it now intends to meet with the US Food and Drug Administration (FDA) to discuss a potential pathway to approval.
